[Molecular targeting drugs--present status and future development].
Development of molecular targeting drugs is a recent highlight in cancer therapeutic field. One can look for 'drugable' target(s) from many molecular targets specific in malignant characteristics of human cancers. Drugs targeting various malignancy-linked molecules such as EGF receptor and its family proteins. Bcr-abl, CD20, Ras and others are now approved or under clinical trials against cancer patients. These molecular targeting drugs will provide a novel and useful therapeutic strategy, but, at the same time, we have many problems to overcome. We should continue our further efforts to answer following problems: (1) How therapeutic efficacy of molecular targeting drugs could be determined in patients in evidence-based manner?; (2) What is promising molecular target for development of drug?; (3) How combination therapy of molecular targeting drug with other cytotoxic drugs should be designed?
Research Center for Innovative Cancer Therapy, Kurume University.
Michihiko
M
Kuwano
Teruhiko
T
Fujii
Mayumi
M
Ono
Hiroto
H
Izumi
Kimitoshi
K
Kohno
D000970:Antineoplastic Agents / Q000008:administration & dosage; D016503:Drug Delivery Systems / Q000639:trends*; D005544:Forecasting; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology
D000970:Antineoplastic Agents